

CRISPR and CRISPR-Associated (Cas) Genes Industry Research Report 2024

<https://marketpublishers.com/r/C741AA8CF544EN.html>

Date: April 2024

Pages: 129

Price: US\$ 2,950.00 (Single User License)

ID: C741AA8CF544EN

Abstracts

Summary

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of *Francisella novicida*. Other such systems are thought to exist. CRISPR/Edits Medicines2 from the bacterium *Leptotrichia shahii* is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have

many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

According to APO Research, The global CRISPR and CRISPR-Associated (Cas) Genes market was valued at US\$ million in 2023 and is anticipated to reach US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of CRISPR and CRISPR-Associated (Cas) Genes include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Celectis, Horizon Discovery Plc, Sigma Aldrich and Precision Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for CRISPR and CRISPR-Associated (Cas) Genes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRISPR and CRISPR-Associated (Cas) Genes.

The CRISPR and CRISPR-Associated (Cas) Genes market size, estimations, and forecasts are provided in terms of revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report

segments the global CRISPR and CRISPR-Associated (Cas) Genes market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Thermo Fisher Scientific

Editas Medicine

Caribou Biosciences

CRISPR therapeutics

Intellia therapeutics, Inc.

Cellectis

Horizon Discovery Plc

Sigma Aldrich

Precision Biosciences

Genscript

Sangamo Biosciences Inc.

Lonza Group Limited

Integrated DNA Technologies

New England Biolabs

Origene Technologies

CRISPR and CRISPR-Associated (Cas) Genes segment by Type

Genome Editing

Genetic engineering

gRNA Database/Gene Librar

CRISPR Plasmid

Human Stem Cells

Genetically Modified Organisms/Crops

Cell Line Engineering

CRISPR and CRISPR-Associated (Cas) Genes Segment by Application

Biotechnology Companies

Pharmaceutical Companies

Academic Institutes

Research and Development Institutes

CRISPR and CRISPR-Associated (Cas) Genes Segment by Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size,

this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 CRISPR and CRISPR-Associated (Cas) Genes by Type
 - 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
 - 2.2.2 Genome Editing
 - 2.2.3 Genetic engineering
 - 2.2.4 gRNA Database/Gene Librar
 - 2.2.5 CRISPR Plasmid
 - 2.2.6 Human Stem Cells
 - 2.2.7 Genetically Modified Organisms/Crops
 - 2.2.8 Cell Line Engineering
- 2.3 CRISPR and CRISPR-Associated (Cas) Genes by Application
 - 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
 - 2.3.2 Biotechnology Companies
 - 2.3.3 Pharmaceutical Companies
 - 2.3.4 Academic Institutes
 - 2.3.5 Research and Development Institutes
- 2.4 Assumptions and Limitations

3 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES BREAKDOWN DATA BY TYPE

- 3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Historic Market Size by Type (2019-2024)
- 3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Type (2025-2030)

4 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES BREAKDOWN DATA BY APPLICATION

4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Historic Market Size by Application (2019-2024)

4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Perspective (2019-2030)

5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Growth Trends by Region

5.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region: 2019 VS 2023 VS 2030

5.2.2 CRISPR and CRISPR-Associated (Cas) Genes Historic Market Size by Region (2019-2024)

5.2.3 CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Region (2025-2030)

5.3 CRISPR and CRISPR-Associated (Cas) Genes Market Dynamics

5.3.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends

5.3.2 CRISPR and CRISPR-Associated (Cas) Genes Market Drivers

5.3.3 CRISPR and CRISPR-Associated (Cas) Genes Market Challenges

5.3.4 CRISPR and CRISPR-Associated (Cas) Genes Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top CRISPR and CRISPR-Associated (Cas) Genes Players by Revenue

6.1.1 Global Top CRISPR and CRISPR-Associated (Cas) Genes Players by Revenue (2019-2024)

6.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2019-2024)

6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Industry Players Ranking, 2022 VS 2023 VS 2024

6.3 Global Key Players of CRISPR and CRISPR-Associated (Cas) Genes Head office and Area Served

6.4 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application

6.5 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Date of Enter into This Industry

6.6 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)

7.2 North America CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 North America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2019-2024)

7.4 North America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2025-2030)

7.5 United States

7.6 Canada

8 EUROPE

8.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)

8.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2019-2024)

8.4 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2025-2030)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Russia

8.10 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)

9.2 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by

Country: 2019 VS 2023 VS 2030

9.3 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2019-2024)

9.4 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2025-2030)

9.5 China

9.6 Japan

9.7 South Korea

9.8 Southeast Asia

9.9 India

9.10 Australia

10 LATIN AMERICA

10.1 Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)

10.2 Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2019-2024)

10.4 Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2025-2030)

10.5 Mexico

10.6 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)

11.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2019 VS 2023 VS 2030

11.3 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2019-2024)

11.4 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2025-2030)

11.5 Turkey

11.6 Saudi Arabia

11.7 UAE

12 PLAYERS PROFILED

12.1 Thermo Fisher Scientific

12.1.1 Thermo Fisher Scientific Company Information

12.1.2 Thermo Fisher Scientific Business Overview

12.1.3 Thermo Fisher Scientific Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.1.5 Thermo Fisher Scientific Recent Developments

12.2 Editas Medicine

12.2.1 Editas Medicine Company Information

12.2.2 Editas Medicine Business Overview

12.2.3 Editas Medicine Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.2.5 Editas Medicine Recent Developments

12.3 Caribou Biosciences

12.3.1 Caribou Biosciences Company Information

12.3.2 Caribou Biosciences Business Overview

12.3.3 Caribou Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.3.5 Caribou Biosciences Recent Developments

12.4 CRISPR therapeutics

12.4.1 CRISPR therapeutics Company Information

12.4.2 CRISPR therapeutics Business Overview

12.4.3 CRISPR therapeutics Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.4.5 CRISPR therapeutics Recent Developments

12.5 Intellia therapeutics, Inc.

12.5.1 Intellia therapeutics, Inc. Company Information

12.5.2 Intellia therapeutics, Inc. Business Overview

12.5.3 Intellia therapeutics, Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.5.5 Intellia therapeutics, Inc. Recent Developments

12.6 Collectis

12.6.1 Collectis Company Information

12.6.2 Collectis Business Overview

12.6.3 Collectis Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.6.4 Collectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.6.5 Collectis Recent Developments

12.7 Horizon Discovery Plc

12.7.1 Horizon Discovery Plc Company Information

12.7.2 Horizon Discovery Plc Business Overview

12.7.3 Horizon Discovery Plc Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.7.5 Horizon Discovery Plc Recent Developments

12.8 Sigma Aldrich

12.8.1 Sigma Aldrich Company Information

12.8.2 Sigma Aldrich Business Overview

12.8.3 Sigma Aldrich Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.8.5 Sigma Aldrich Recent Developments

12.9 Precision Biosciences

12.9.1 Precision Biosciences Company Information

12.9.2 Precision Biosciences Business Overview

12.9.3 Precision Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

12.9.5 Precision Biosciences Recent Developments

12.10 Genscript

12.10.1 Genscript Company Information

12.10.2 Genscript Business Overview

12.10.3 Genscript Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)

12.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio

- 12.10.5 Genscript Recent Developments
- 12.11 Sangamo Biosciences Inc.
 - 12.11.1 Sangamo Biosciences Inc. Company Information
 - 12.11.2 Sangamo Biosciences Inc. Business Overview
 - 12.11.3 Sangamo Biosciences Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)
 - 12.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
 - 12.11.5 Sangamo Biosciences Inc. Recent Developments
- 12.12 Lonza Group Limited
 - 12.12.1 Lonza Group Limited Company Information
 - 12.12.2 Lonza Group Limited Business Overview
 - 12.12.3 Lonza Group Limited Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)
 - 12.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
 - 12.12.5 Lonza Group Limited Recent Developments
- 12.13 Integrated DNA Technologies
 - 12.13.1 Integrated DNA Technologies Company Information
 - 12.13.2 Integrated DNA Technologies Business Overview
 - 12.13.3 Integrated DNA Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)
 - 12.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
 - 12.13.5 Integrated DNA Technologies Recent Developments
- 12.14 New England Biolabs
 - 12.14.1 New England Biolabs Company Information
 - 12.14.2 New England Biolabs Business Overview
 - 12.14.3 New England Biolabs Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)
 - 12.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
 - 12.14.5 New England Biolabs Recent Developments
- 12.15 Origene Technologies
 - 12.15.1 Origene Technologies Company Information
 - 12.15.2 Origene Technologies Business Overview
 - 12.15.3 Origene Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2019-2024)
 - 12.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product

Portfolio

12.15.5 Origene Technologies Recent Developments

13 REPORT CONCLUSION

14 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2018-2023)

Table 7. Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2024-2029)

Table 9. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application (2018-2023) & (US\$ Million)

Table 10. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2018-2023)

Table 11. Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 12. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2024-2029)

Table 13. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2018-2023)

Table 16. Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2024-2029)

Table 18. CRISPR and CRISPR-Associated (Cas) Genes Market Trends

Table 19. CRISPR and CRISPR-Associated (Cas) Genes Market Drivers

Table 20. CRISPR and CRISPR-Associated (Cas) Genes Market Challenges

Table 21. CRISPR and CRISPR-Associated (Cas) Genes Market Restraints

Table 22. Global Top CRISPR and CRISPR-Associated (Cas) Genes Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of CRISPR and CRISPR-Associated (Cas) Genes, Headquarters and Area Served

Table 26. Global CRISPR and CRISPR-Associated (Cas) Genes Manufacturers, Product Type & Application

Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 28. Global CRISPR and CRISPR-Associated (Cas) Genes by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. North America CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. North America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2018-2023) & (US\$ Million)

Table 32. North America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2024-2029) & (US\$ Million)

Table 33. Europe CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 34. Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2018-2023) & (US\$ Million)

Table 35. Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 37. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 40. Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Latin America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market

Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Thermo Fisher Scientific Company Detail

Table 46. Thermo Fisher Scientific Business Overview

Table 47. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product

Table 48. Thermo Fisher Scientific Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 49. Thermo Fisher Scientific Recent Development

Table 50. Editas Medicine Company Detail

Table 51. Editas Medicine Business Overview

Table 52. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product

Table 53. Editas Medicine Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 54. Editas Medicine Recent Development

Table 55. Caribou Biosciences Company Detail

Table 56. Caribou Biosciences Business Overview

Table 57. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product

Table 58. Caribou Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 59. Caribou Biosciences Recent Development

Table 60. CRISPR therapeutics Company Detail

Table 61. CRISPR therapeutics Business Overview

Table 62. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product

Table 63. CRISPR therapeutics Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 64. CRISPR therapeutics Recent Development

Table 65. Intellia therapeutics, Inc. Company Detail

Table 66. Intellia therapeutics, Inc. Business Overview

Table 67. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product

Table 68. Intellia therapeutics, Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 69. Intellia therapeutics, Inc. Recent Development

Table 70. Cellectis Company Detail

Table 71. Cellectis Business Overview

- Table 72. Collectis CRISPR and CRISPR-Associated (Cas) Genes Product
- Table 73. Collectis Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)
- Table 74. Collectis Recent Development
- Table 75. Horizon Discovery Plc Company Detail
- Table 76. Horizon Discovery Plc Business Overview
- Table 77. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product
- Table 78. Horizon Discovery Plc Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)
- Table 79. Horizon Discovery Plc Recent Development
- Table 80. Sigma Aldrich Company Detail
- Table 81. Sigma Aldrich Business Overview
- Table 82. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product
- Table 83. Sigma Aldrich Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)
- Table 84. Sigma Aldrich Recent Development
- Table 85. Precision Biosciences Company Detail
- Table 86. Precision Biosciences Business Overview
- Table 87. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product
- Table 88. Precision Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)
- Table 89. Precision Biosciences Recent Development
- Table 90. Genscript Company Detail
- Table 91. Genscript Business Overview
- Table 92. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product
- Table 93. Genscript Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)
- Table 94. Genscript Recent Development
- Table 95. Sangamo Biosciences Inc. Company Detail
- Table 96. Sangamo Biosciences Inc. Business Overview
- Table 97. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) GenesProduct
- Table 98. Sangamo Biosciences Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)
- Table 99. Sangamo Biosciences Inc. Recent Development
- Table 100. Lonza Group Limited Company Detail
- Table 101. Lonza Group Limited Business Overview

Table 102. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) GenesProduct

Table 103. Lonza Group Limited Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 104. Lonza Group Limited Recent Development

Table 105. Integrated DNA Technologies Company Detail

Table 106. Integrated DNA Technologies Business Overview

Table 107. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) GenesProduct

Table 108. Integrated DNA Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 109. Integrated DNA Technologies Recent Development

Table 110. New England Biolabs Company Detail

Table 111. New England Biolabs Business Overview

Table 112. New England Biolabs CRISPR and CRISPR-Associated (Cas) GenesProduct

Table 113. New England Biolabs Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 114. New England Biolabs Recent Development

Table 115. Origene Technologies Company Detail

Table 116. Origene Technologies Business Overview

Table 117. Origene Technologies CRISPR and CRISPR-Associated (Cas) GenesProduct

Table 118. Origene Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2017-2022) & (US\$ Million)

Table 119. Origene Technologies Recent Development

Table 120. Thermo Fisher Scientific Company Information

Table 121. Thermo Fisher Scientific Business Overview

Table 122. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)

Table 123. Thermo Fisher Scientific Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio

Table 124. Thermo Fisher Scientific Recent Development

Table 125. Editas Medicine Company Information

Table 126. Editas Medicine Business Overview

Table 127. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)

Table 128. Editas Medicine Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio

- Table 129. Editas Medicine Recent Development
- Table 130. Caribou Biosciences Company Information
- Table 131. Caribou Biosciences Business Overview
- Table 132. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 133. Caribou Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 134. Caribou Biosciences Recent Development
- Table 135. CRISPR therapeutics Company Information
- Table 136. CRISPR therapeutics Business Overview
- Table 137. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 138. CRISPR therapeutics Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 139. CRISPR therapeutics Recent Development
- Table 140. Intellia therapeutics, Inc. Company Information
- Table 141. Intellia therapeutics, Inc. Business Overview
- Table 142. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 143. Intellia therapeutics, Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 144. Intellia therapeutics, Inc. Recent Development
- Table 145. Collectis Company Information
- Table 146. Collectis Business Overview
- Table 147. Collectis CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 148. Collectis Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 149. Collectis Recent Development
- Table 150. Horizon Discovery Plc Company Information
- Table 151. Horizon Discovery Plc Business Overview
- Table 152. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 153. Horizon Discovery Plc Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio

- Table 154. Horizon Discovery Plc Recent Development
- Table 155. Sigma Aldrich Company Information
- Table 156. Sigma Aldrich Business Overview
- Table 157. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 158. Sigma Aldrich Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 159. Sigma Aldrich Recent Development
- Table 160. Precision Biosciences Company Information
- Table 161. Precision Biosciences Business Overview
- Table 162. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 163. Precision Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 164. Precision Biosciences Recent Development
- Table 165. Genscript Company Information
- Table 166. Genscript Business Overview
- Table 167. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 168. Genscript Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 169. Genscript Recent Development
- Table 170. Sangamo Biosciences Inc. Company Information
- Table 171. Sangamo Biosciences Inc. Business Overview
- Table 172. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 173. Sangamo Biosciences Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 174. Sangamo Biosciences Inc. Recent Development
- Table 175. Lonza Group Limited Company Information
- Table 176. Lonza Group Limited Business Overview
- Table 177. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)
- Table 178. Lonza Group Limited Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio
- Table 179. Lonza Group Limited Recent Development

Table 180. Integrated DNA Technologies Company Information

Table 181. Integrated DNA Technologies Business Overview

Table 182. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)

Table 183. Integrated DNA Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio

Table 184. Integrated DNA Technologies Recent Development

Table 185. New England Biolabs Company Information

Table 186. New England Biolabs Business Overview

Table 187. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)

Table 188. New England Biolabs Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio

Table 189. New England Biolabs Recent Development

Table 190. Origene Technologies Company Information

Table 191. Origene Technologies Business Overview

Table 192. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million)

Table 193. Origene Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2018-2023) & (US\$ Million) Portfolio

Table 194. Origene Technologies Recent Development

Table 195. Authors List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. CRISPR and CRISPR-Associated (Cas) Genes Product Picture

Figure 5. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 6. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Type: 2022 VS 2029

Figure 7. Genome Editing Product Picture

Figure 8. Genetic engineering Product Picture

Figure 9. gRNA Database/Gene Librar Product Picture

Figure 10. CRISPR Plasmid Product Picture

Figure 11. Human Stem Cells Product Picture

Figure 12. Genetically Modified Organisms/Crops Product Picture

Figure 13. Cell Line Engineering Product Picture

Figure 14. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application (2023-2029) & (US\$ Million)

Figure 15. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Application: 2022 VS 2029

Figure 16. Biotechnology Companies Product Picture

Figure 17. Pharmaceutical Companies Product Picture

Figure 18. Academic Institutes Product Picture

Figure 19. Research and Development Institutes Product Picture

Figure 20. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 21. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region: 2022 VS 2029

Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Players in 2022

Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Players, Date of Enter into This Industry

Figure 25. Global Top 5 and 10 CRISPR and CRISPR-Associated (Cas) Genes Players Market Share by Revenue in 2022

Figure 26. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 27. North America CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. North America CRISPR and CRISPR-Associated (Cas) Genes Market Share by Country (2018-2029)

Figure 29. United States CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Canada CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Europe CRISPR and CRISPR-Associated (Cas) Genes Market Share by Country (2018-2029)

Figure 33. Germany CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. France CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. U.K. CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Italy CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Russia CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Share by Country (2018-2029)

Figure 41. China CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Japan CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. South Korea CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. India CRISPR and CRISPR-Associated (Cas) Genes Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Australia

I would like to order

Product name: CRISPR and CRISPR-Associated (Cas) Genes Industry Research Report 2024

Product link: <https://marketpublishers.com/r/C741AA8CF544EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C741AA8CF544EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970